MBX Biosciences, Inc. 8-K

What Happened
MBX Biosciences, Inc. announced its financial results for the quarter ended March 31, 2026 and furnished a press release with those results as Exhibit 99.1 to a Form 8‑K filed on May 7, 2026 (Item 2.02: Results of Operations and Financial Condition). The Form 8‑K was signed by P. Kent Hawryluk, President and Chief Executive Officer.

Key Details

• Filing date: May 7, 2026; reporting quarter: ended March 31, 2026.
• The company furnished a press release containing the quarterly financial results as Exhibit 99.1.
• The filing includes the interactive cover page XBRL file as Exhibit 104.
• Form 8‑K was signed by CEO P. Kent Hawryluk (authorized signatory).

Why It Matters
This 8‑K provides the company’s latest quarterly earnings/financial results and related press release; investors should review the Exhibit 99.1 press release for revenue, profit/loss, guidance or other performance metrics. Because the filing furnishes (rather than amends) the press release, any material numbers or updates will be found in the attached exhibit and in subsequent SEC filings if the company provides additional detail.